weighing balance [30:5 x ULN at End of Treatment (EOT)) Complicated Urinary Tract Infections (one trial) Complicated Intra-Abdominal Infections (two trials) Other Phase 3 Trials (two trials) System organ class Doribax 500 mg administered every 8 hours (n =376 ) Levofloxacin 250 mg administered IV every 24 hours (n = 372) Doribax 500 mg administered every 8 hours (n = 477) Meropenem 1 g administered every 8 hours (n = 469) Doribax 500 mg administered every 8 hours (n =485 ) Comparator * (n=484) Nervous system disorders Headache 16 15 4 5 3 3 Vascular disorders Phlebitis 4 4 8 6 2 1 Gastro-intestinal disorders Nausea 4 6 12 9 7 7 Diarrhea 6 10 11 11 12 14 C . difficile colitis] FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only B Pregnancy Category No proven risk in humans N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Manufacturers Johnson & Johnson Shionogi Inc. Drug Class Carbapenems Related Drugs carbapenems meropenem , Invanz , ertapenem , cilastatin / imipenem , Merrem , Primaxin IV Kidney Infections ciprofloxacin , cephalexin , Augmentin , Levaquin , Keflex , levofloxacin , Bactrim , More... Intraabdominal Infection ciprofloxacin , metronidazole , clindamycin , ceftriaxone , Flagyl , Rocephin , gentamicin , More... Urinary Tract Infection ciprofloxacin , amoxicillin , doxycycline , Augmentin , Levaquin , levofloxacin , Bactrim , More... Doribax Rating 1 User Review 10 /10 1 User Review 10 Rate it! pattern
an in depth Doribax corporation
EmoticonEmoticon